Protocol #1-2009 (Published in American Heart J)

**Title:** Transradial versus transfemoral percutaneous coronary intervention in acute myocardial infarction: Systematic overview and meta-analysis

**Highlights:** Clinical studies comparing the safety and efficacy of the transradial and transfemoral vascular accesses in ST-segment elevation myocardial infarction will be systematically searched, appraised and pooled with meta-analytic methods

**Search strategy:** PubMed, SCOPUS, the Web of Science and CENTRAL will be searched for pertinent articles according to the following highly sensitive strategy: transradial OR infarct* OR radial access OR myocardial AND coronary

**Principal investigator:** András Vorobcsuk, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary

Protocol #1-2010 (Published in American Heart J)

**Title:** Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis

**Highlights:** Collect and summarize the available evidence regarding the prognostic significance of high on-clopidogrel platelet reactivity (HPR) to achieve greater statistical power and more precise effect estimates.

**Search strategy:** PubMed and CENTRAL will be searched for pertinent articles according to the following highly sensitive strategy: clopidogrel AND resistance OR platelet reactivity OR outcome OR prognostic

**Principal Investigator:** Dániel Aradi, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary

Protocol #1-2011 (Published in International Journal of Cardiology)

**Title:** Outcomes of patients receiving clopidogrel prior to cardiac surgery

**Highlights:** Clinical studies to evaluate the impact of clopidogrel treatment on clinical outcomes in patients undergoing cardiac surgery will be systematically searched, appraised and pooled with meta-analytic methods

**Search strategy:** PubMed and CENTRAL will be searched for pertinent articles according to the following highly sensitive strategy: CABG AND/OR clopidogrel AND/OR prognosis AND/OR bleeding, transfusion AND/OR reoperation AND/OR mortality

**Principal investigator:** András Vorobcsuk, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary

Protocol #2-2011 (Published in Rheumatology)

**Title:** The impact of cardio-pulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies

**Highlights:** Collect and summarize the available evidence regarding the incidence and prognostic significance of cardiopulmonary manifestations in SSc in order to achieve better statistical power, define more precise effect estimates of different internal organ manifestations and verify trends in mortality of SSc

**Search strategy:** PubMed, the Web of Science and CENTRAL will be searched for pertinent articles according to the following highly sensitive strategy: scleroderma OR systemic AND sclerosis AND (mortality [mh]OR survival [mh] OR outcome [mh] OR prognosis [mh])

**Principal investigator:** András Komócsi, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary

Protocol #1-2012 (ongoing)

**Title:** Antiplatelet agents on stroke compared to clopidogrel in patients with coronary artery disease

**Highlights:** Clinical studies to evaluate whether new ADP-receptor inhibitors are better than clopidogrel in stroke prevention will be systematically searched, appraised and pooled with meta-analytic methods

**Search strategy:** PubMed, www.clinicaltrials.gov and Scopus will be searched for pertinent articles according to the following highly sensitive strategy: **coronary artery disease'** ("coronary disease"[MeSH Terms] OR ("coronary"[All Fields] AND "disease"[All Fields]) OR "coronary disease"[All Fields]) **and 'stroke'** ("stroke"[MeSH Terms] OR "stroke"[All Fields]) **and 'ADP receptor inhibitors'** ("receptors, purinergic p2"[MeSH Terms] OR ("receptors"[All Fields] AND "purinergic"[All Fields] AND "p2"[All Fields]) OR "purinergic p2 receptors"[All Fields] OR ("adp"[All Fields] AND "receptor"[All Fields]) OR "adp receptor"[All Fields]) AND ("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])

**Principal investigator:** Dániel Aradi, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary

Protocol#2-2012 (ongoing)

**Title:** Transradial versus Transfemoral Percutaneous Coronary Intervention in ST-segment Elevation Myocardial infarction: an Updated Bayesian Meta-analysis

**Highlights:** Since important, well designed RCTs have been published recently, our objective was to review and update the meta-analysis of the safety and efficacy of TRPCI versus TFPCI in the setting of

STEMI. Moreover, we also aimed to corroborate our analysis with a hierarchical Bayesian comparison to find out whether the hypotheses suggested by OTs were relevant in the context of RCTs

**Search strategy:** Electronic databases will be searched for pertinent articles according to the following highly sensitive strategy: transradial OR transfemoral OR radial access OR STEMI OR myocardial OR infarct

**Principal investigator:** András Komócsi, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary

Protocol#3-2012 (ongoing)

**Title:** Efficacy and Safety of Intensified Antiplatelet Therapy on the Basis of Platelet Reactivity Testing in Patients After Percutaneous Coronary Interventions: Systematic Review and Meta-Analysis

**Highlights:** a systematic review and meta-analysis of randomized clinical trials in order to evaluate the clinical efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing versus standard dose clopidogrel in PCI-treated patients with HTPR

**Search strategy:** Electronic databases will be searched for pertinent articles according to the following highly sensitive strategy: tailored antiplatelet treatment OR clopidogrel resistance OR platelet function monitoring OR 150 mg clopidogrel OR high platelet reactivity OR prasugrel

**Principal investigator:** Dániel Aradi, University of Pécs, Heart Institute, Department of Interventional Cardiology, Pécs, Hungary